Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 2
2003 3
2004 1
2005 1
2006 4
2007 3
2008 7
2009 8
2010 15
2011 17
2012 9
2013 9
2014 13
2015 10
2016 8
2017 6
2018 3
2019 7
2020 3
2021 3
2022 4
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.
Amini-Adle M, Arnault JP, Aubin F, Beneton N, Bens G, Brunet-Possenti F, Célerier P, Charles J, Crumbach L, Dalac S, Darras S, De Quatrebarbes J, Dinulescu M, Dutriaux C, Gaudy C, Gérard E, Giacchero D, Granel-Brocard F, Grange F, Jouary T, Kramkimel N, Lebbé C, Le Corre Y, Legoupil D, Lesage C, Lesimple T, Lorphelin JM, Mansard S, Martin L, Mary-Prey S, Maubec E, Meyer N, Mignard C, Montaudie H, Mortier L, Nardin C, Neidhardt Berard EM, Pagès Laurent C, Peuvrel L, Quereux G, Robert C, Saiag P, Saint-Jean M, Samimi M, Sassolas B, Scalbert C, Skowron F, Steff M, Stoebner PE, Trablesi S, Visseaux L, Zehou O, Boespflug A; GCC group Groupe Cancérologie Cutanée – Cutaneous Oncology Group, the Ethical Group of the Société Française de Dermatologie French Dermatology Group. Amini-Adle M, et al. Among authors: jouary t. Ann Dermatol Venereol. 2024 Mar;151(1):103243. doi: 10.1016/j.annder.2023.103243. Epub 2024 Feb 6. Ann Dermatol Venereol. 2024. PMID: 38325268 No abstract available.
Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
Nardin C, Hennemann A, Diallo K, Funck-Brentano E, Puzenat E, Heidelberger V, Jeudy G, Samimi M, Lesage C, Boussemart L, Peuvrel L, Rouanet J, Brunet-Possenti F, Gerard E, Seris A, Jouary T, Saint-Jean M, Puyraveau M, Saiag P, Aubin F. Nardin C, et al. Among authors: jouary t. Cancers (Basel). 2023 Jul 10;15(14):3564. doi: 10.3390/cancers15143564. Cancers (Basel). 2023. PMID: 37509227 Free PMC article.
Sweat Gland Tumors Arising on Acral Sites: A Molecular Survey.
Kervarrec T, Tallet A, Macagno N, de la Fouchardière A, Pissaloux D, Tirode F, Bravo IG, Nicolas A, Baulande S, Sohier P, Balme B, Osio A, Jullie ML, Moulonguet I, Bonsang B, Tournier E, Herfs M, Frouin E, Zidan A, Calonje E, Berthon P, Touzé A, Seris A, Mortier L, Jouary T, Cribier B, Battistella M. Kervarrec T, et al. Among authors: jouary t. Am J Surg Pathol. 2023 Oct 1;47(10):1096-1107. doi: 10.1097/PAS.0000000000002098. Epub 2023 Jul 31. Am J Surg Pathol. 2023. PMID: 37505808 Free article.
Digital Papillary Adenocarcinoma in Nonacral Skin: Clinicopathologic and Genetic Characterization of 5 Cases.
Kervarrec T, Imbeaud S, Veyer D, Pere H, Puech J, Pekár-Lukacs A, Markiewicz D, Coutts M, Tallet A, Collin C, Berthon P, Bravo IG, Seris A, Jouary T, Macagno N, Touzé A, Cribier B, Battistella M, Calonje E. Kervarrec T, et al. Among authors: jouary t. Am J Surg Pathol. 2023 Oct 1;47(10):1077-1084. doi: 10.1097/PAS.0000000000002096. Epub 2023 Jul 31. Am J Surg Pathol. 2023. PMID: 37505796
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas.
Toulemonde E, Chevret S, Battistella M, Neidhardt EM, Nardin C, Le Du F, Meyer N, Véron M, Gambotti L, Lamrani-Ghaouti A, Jamme P, Chaffaut C, De Pontville M, Saada-Bouzid E, Beylot-Barry M, Simon C, Jouary T, Marabelle A, Mortier L. Toulemonde E, et al. Among authors: jouary t. Cancer Immunol Immunother. 2023 Aug;72(8):2649-2657. doi: 10.1007/s00262-023-03449-9. Epub 2023 Apr 17. Cancer Immunol Immunother. 2023. PMID: 37067554 Free PMC article.
Severity of Local Skin Reactions with 4% 5-Fluorouracil Plus Emollient versus 4% 5-Fluorouracil Alone in Patients with Actinic Keratosis: A Single-Blind Randomised Trial.
Stockfleth E, Jouary T, Farnetani F, Pascual AM, De Almeida Agudo C, Voisard JJ, Bégeault N, Delarue A. Stockfleth E, et al. Among authors: jouary t. Dermatol Ther (Heidelb). 2023 Apr;13(4):1013-1027. doi: 10.1007/s13555-023-00902-6. Epub 2023 Mar 1. Dermatol Ther (Heidelb). 2023. PMID: 36856965 Free PMC article.
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
Véron M, Chevret S, Grob JJ, Beylot-Barry M, Saiag P, Fléchon A, You B, Maubec E, Jouary T, Toulemonde E, Jamme P, Gambotti L, Lamrani-Ghaouti A, Dupuy A, Lebbe C, Seguin NB, Houede N, Leccia MT, Le Du F, de Pontville M, Gaudy-Marquestre C, Guillot B, Simon C, Marabelle A, Mortier L. Véron M, et al. Among authors: jouary t. Eur J Cancer. 2022 Dec;177:103-111. doi: 10.1016/j.ejca.2022.09.013. Epub 2022 Oct 11. Eur J Cancer. 2022. PMID: 36335780 Clinical Trial.
Impact of expert pathology review in skin adnexal carcinoma diagnosis: Analysis of 2573 patients from the French CARADERM network.
Battistella M, Balme B, Jullie ML, Zimmermann U, Carlotti A, Crinquette M, Frouin E, Macagno N, Ortonne N, Lamant L, de la Fouchardiere A, Aubriot-Lorton MH, Durand L, Josselin N, Franck F, Chatelain D, Lemasson G, Algros MP, Durlach A, Machet MC, Courville P, Osio A, Seris A, Mortier L, Jouary T, Cribier B; CARADERM network. Battistella M, et al. Among authors: jouary t. Eur J Cancer. 2022 Mar;163:211-221. doi: 10.1016/j.ejca.2021.11.027. Epub 2022 Jan 30. Eur J Cancer. 2022. PMID: 35090811
Recurrent FOXK1::GRHL and GPS2::GRHL fusions in trichogerminoma.
Kervarrec T, Pissaloux D, Poilane J, Tirode F, Tallet A, Collin C, Tallegas M, Berthon P, Gaboriaud P, Sohier P, Calonje E, Luzar B, Goto K, Cokelaere K, Lamant L, Balme B, Wild R, Neuville A, Deschamps L, Auberger E, Paumier V, Bonte H, Moulonguet I, Plantier F, Cales V, Pinsolle V, Roblet D, Dupuy F, Dallot A, Seris A, Jouary T, Houben R, Schrama D, Hesbacher S, Macagno N, Battistella M, Cribier B, Vergier B, de la Fouchardière A, Jullie ML. Kervarrec T, et al. Among authors: jouary t. J Pathol. 2022 May;257(1):96-108. doi: 10.1002/path.5872. Epub 2022 Mar 28. J Pathol. 2022. PMID: 35049062
Vismodegib efficacy in unresectable trichoblastic carcinoma: A multicenter study of 16 cases.
Duplaine A, Beylot-Barry M, Mansard S, Arnault JP, Grob JJ, Maillard H, Saiag P, Poulalhon N, Cribier B, Mortier L, Battistella M, Jouary T. Duplaine A, et al. Among authors: jouary t. J Am Acad Dermatol. 2022 Jun;86(6):1365-1366. doi: 10.1016/j.jaad.2021.05.024. Epub 2021 May 27. J Am Acad Dermatol. 2022. PMID: 34052337 No abstract available.
124 results